Loading...
Loading...
KDNY| Name | Value |
|---|---|
| Revenues | 0.5M |
| Cost of Revenue | 0.4M |
| Gross Profit | 0.1M |
| Operating Expense | 53.1M |
| Operating I/L | -59.9M |
| Other Income/Expense | 2.4M |
| Interest Income | 0.0M |
| Pretax | -57.5M |
| Income Tax Expense | 4.3M |
| Net Income/Loss | -61.8M |
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company specializing in precision medicines for kidney diseases. Their lead clinical program, atrasentan, is a Phase III endothelin receptor antagonist designed for the treatment of IgA nephropathy and other proteinuric glomerular diseases. The company's product pipeline also includes BION-1301, an anti-APRIL monoclonal antibody being evaluated in a Phase I/II trial for IgA nephropathy, and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria. Additionally, they have ongoing research programs for other rare and severe chronic kidney diseases.
